Earnings Call · Q3 FY2023·2023-11-09

Q3 23EPS -25.00%·Rev n/aQ2 23EPS -100.00%*·Rev n/aQ1 23EPS +4.17%·Rev n/aQ4 22EPS +3.85%·Rev n/a⚠ consensus missing

IRONWOOD PHARMACEUTICALS INC IRWD

Matt Roache — Director

Tom McCourt — Executive, likely CEO or President

Mike Shetzline — Executive, likely in R&D or Clinical Development

Sravan Emany — Executive, likely in Commercial or Sales

+3.1%1d on move date+3.9% vs SPY3d+1.7%5d+5.7%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IRWD calls or request research access.

More IRWD calls Browse calls Request research access